(Q22305948)

7 February 2023

Rob PM Baltussen

2

Rob Pm

Baltussen

1 reference

7 February 2023

Abraham M Palache

series ordinal

3

author given names

Abraham M

author last names

Palache

1 reference

7 February 2023

Jan C Wilschut

series ordinal

4

author given names

Jan C

author last names

Wilschut

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

7 February 2023

language of work or name

English

0 references

publication date

April 2006

0 references

published in

0 references

volume

6

0 references

issue

2

0 references

page(s)

215-227

0 references

cites work

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Public health. Will vaccines be available for the next influenza pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Cost-effectiveness study on influenza prevention in Hong Kong.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Economic evaluation of vaccination against influenza in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Estimating influenza-related hospitalization in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Pandemic Influenza and Healthcare Demand in the Netherlands: Scenario Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

An exercise on the feasibility of carrying out secondary economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Annual revaccination against influenza and mortality risk in community-dwelling elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Additive preventive effect of influenza and pneumococcal vaccines in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Antiviral agents for influenza: a comparison of cost-effectiveness data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Impact of respiratory virus infections on persons with chronic underlying conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Influenza vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Economic impact of influenza vaccination in preschool children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

The Effectiveness of Vaccination against Influenza in Healthy, Working Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Economic evaluation of strategies for the control and management of influenza in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

The 23-Valent Pneumococcal Polysaccharide Vaccine. Part II. A Cost-Effectiveness Analysis for Invasive Disease in the Elderly in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Economic evaluation of influenza vaccination. Assessment for The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Pharmacoeconomic research

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Community pharmacists as immunization advocates. Cost-effectiveness of a cue to influenza vaccination.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Prevention of influenza in the elderly

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.2.215

7 January 2021

Identifiers

DOI

10.1586/14737167.6.2.215

0 references